Literature DB >> 26366561

Understanding Microbiome Data: A Primer for Clinicians.

Philippe Seksik, Cécilia Landman.   

Abstract

The human gut contains 1014 bacteria and many other micro-organisms such as Archaea, viruses and fungi. This gut microbiota has co-evolved with host determinants through symbiotic and co-dependent relationships. Bacteria, which represent 10 times the number of human cells, form the most depicted part of this black box owing to new tools. Re-evaluating the gut microbiota showed how this entity participates in gut physiology and beyond this in human health. Studying and handling this real 'hidden organ' remains a challenge for clinicians. In this review, we aimed to bring information about gut microbiota, its structure, its roles and the way to capture and measure it. After bacterial colonization in infant, intestinal microbial composition is unique for each individual although more than 95% can be assigned to 4 major phyla. Besides its biodiversity, the major characteristics of gut microbiota are stability over time and resilience after perturbation. In pathological situations, dysbiosis (i.e. imbalance in gut microbiota composition) is observed with a loss in overall diversity. Dysbiosis associated with inflammatory bowel disease was specified with the reduction in biodiversity, the decreased representation of different taxa in the Firmicutes phylum and an increase in Gammaproteobacteria. Beyond depicting gut microbial composition, metagenomics allows the description of the combined genomes of the microorganisms present in the gut, giving access to their potential functions. In fact, each individual overall microbial metagenome outnumbers the size of human genome by a factor of 150. Besides a functional core in which there is redundancy for mandatory functions assuring the robustness of the ecosystem, human gut contains an important diversity and high number of non-redundant bacterial genes. Clinical data, treatment and all the factors able to influence microbiome should enter integrated big data sets to put in light pathways of interplay within the supra organism composed of gut microbiome and host. A better understanding of dynamics within human gut microbiota and microbes-host interaction will allow new insight into gut pathophysiology especially regarding resilience mechanisms and dysbiosis onset and maintenance. This will lead to description of biomarkers of diseases, development of new probiotics/prebiotics and new therapies.
© 2015 S. Karger AG, Basel.

Entities:  

Year:  2015        PMID: 26366561     DOI: 10.1159/000437034

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

1.  Aluminum-induced generation of lipopolysaccharide (LPS) from the human gastrointestinal (GI)-tract microbiome-resident Bacteroides fragilis.

Authors:  P N Alexandrov; J M Hill; Y Zhao; T Bond; C M Taylor; M E Percy; W Li; W J Lukiw
Journal:  J Inorg Biochem       Date:  2019-10-22       Impact factor: 4.155

Review 2.  Inflammation Thread Runs across Medical Laboratory Specialities.

Authors:  Urs Nydegger; Thomas Lung; Lorenz Risch; Martin Risch; Pedro Medina Escobar; Thomas Bodmer
Journal:  Mediators Inflamm       Date:  2016-07-14       Impact factor: 4.711

3.  Bacteroides fragilis Lipopolysaccharide and Inflammatory Signaling in Alzheimer's Disease.

Authors:  Walter J Lukiw
Journal:  Front Microbiol       Date:  2016-09-26       Impact factor: 5.640

Review 4.  Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.

Authors:  Marco Poeta; Luca Pierri; Pietro Vajro
Journal:  Children (Basel)       Date:  2017-08-02

Review 5.  Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.

Authors:  Gemma Aragonès; Sergio González-García; Carmen Aguilar; Cristóbal Richart; Teresa Auguet
Journal:  Biomed Res Int       Date:  2019-01-02       Impact factor: 3.411

Review 6.  The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases.

Authors:  Huihui Xu; Meijie Liu; Jinfeng Cao; Xiaoya Li; Danping Fan; Ya Xia; Xiangchen Lu; Jingtao Li; Dahong Ju; Hongyan Zhao
Journal:  J Immunol Res       Date:  2019-10-27       Impact factor: 4.818

7.  Gut microbiota mediates the absorption of FLZ, a new drug for Parkinson's disease treatment.

Authors:  Junmei Shang; Shurong Ma; Caixia Zang; Xiuqi Bao; Yan Wang; Dan Zhang
Journal:  Acta Pharm Sin B       Date:  2021-01-26       Impact factor: 11.413

Review 8.  Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  Int J Mol Sci       Date:  2016-04-01       Impact factor: 5.923

Review 9.  Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism.

Authors:  Hadi Emamat; Hamid Ghalandari; Hadith Tangestani; Afsoun Abdollahi; Azita Hekmatdoost
Journal:  EXCLI J       Date:  2020-05-12       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.